WallStSmart

Becton Dickinson and Company (BDX)vsMedline Inc. Class A Common Stock (MDLN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 30% more annual revenue ($28.43B vs $21.92B). BDX leads profitability with a 8.0% profit margin vs 4.1%. BDX trades at a lower P/E of 25.6x. BDX earns a higher WallStSmart Score of 61/100 (C+).

BDX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 5.5Value: 10.0Quality: 6.5
Piotroski: 6/9Altman Z: 1.49

MDLN

Buy

52

out of 100

Grade: C-

Growth: 7.3Profit: 5.0Value: 8.3Quality: 7.8
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+36.0%)

Margin of Safety

+36.0%

Fair Value

$282.20

Current Price

$154.13

$128.07 discount

UndervaluedFair: $282.20Overvalued
MDLNUndervalued (+32.7%)

Margin of Safety

+32.7%

Fair Value

$66.92

Current Price

$42.73

$24.19 discount

UndervaluedFair: $66.92Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX3 strengths · Avg: 8.3/10
Market CapQuality
$55.84B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

MDLN1 strengths · Avg: 10.0/10
EPS GrowthGrowth
1255.0%10/10

Earnings expanding 1255.0% YoY

Areas to Watch

BDX4 concerns · Avg: 3.3/10
P/E RatioValuation
25.6x4/10

Moderate valuation

Revenue GrowthGrowth
1.6%4/10

1.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

MDLN4 concerns · Avg: 3.0/10
P/E RatioValuation
29.5x4/10

Moderate valuation

Return on EquityProfitability
6.5%3/10

ROE of 6.5% — below average capital efficiency

Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Free Cash FlowQuality
$-113.00M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Market Cap, Price/Book, EPS Growth. PEG of 1.18 suggests the stock is reasonably priced for its growth.

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth. Revenue growth of 14.8% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Revenue Growth, Return on Equity.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Return on Equity, Profit Margin. Thin 4.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

MDLN is growing revenue faster at 14.8% — sustainability is the question.

BDX generates stronger free cash flow (549M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BDX scores higher overall (61/100 vs 52/100). MDLN offers better value entry with a 32.7% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Want to dig deeper into these stocks?